Full-Time

Surgical Technician

NAMSA

NAMSA

1,001-5,000 employees

MedTech CRO delivering end-to-end device development

Compensation Overview

$14.81 - $23/hr

Minneapolis, MN, USA

In Person

Bachelor's, Associate's

Category
Medical, Clinical & Veterinary (1)

Get referred to NAMSA

See people who can refer or advise you

Requirements
  • Bachelor’s degree in scientific discipline or Associate of Applied Science in Veterinary Technology required.
  • 0-2 years related work experience.
Responsibilities
  • Prepares surgical and cath lab suites for procedures, including setting up instruments and stocking study-specific supplies.
  • Monitors anesthesia and animal vitals during surgical interventional procedures.
  • Administers medications intra-procedure.
  • Performs euthanasia.
  • Collects laboratory samples, such as blood and urine, and processes them for analysis.
  • Assists with specialized software-driven equipment, fluoroscopy and 3D imaging, etc. in support of procedures.
  • Provides customer service to clients through professional interactions and by responding to client requests.
  • Prepares and maintains surgical instruments through washing, drying and proper storage. Assembles surgical packs and processes sterile packs via autoclave or ethylene oxide.
  • Operates, cleans and maintains gas anesthesia machines, autoclave and other surgical equipment routinely utilized.
  • Maintains an efficient and clean work area by organizing and re-stocking cath labs, operating rooms, and the general storeroom as needed.
  • Other duties as assigned.
Desired Qualifications
  • Certified Veterinary Technician (CVT) or ALAT certification preferred.
  • Knowledge of research animal physiology, pharmacology and general animal care preferred.

NAMSA is a medical device-focused contract research organization (CRO) that provides end-to-end development services. It helps sponsors bring medical devices to market by offering testing, regulatory and quality consulting, reimbursement support, and clinical research. The way it works is through a global team with regulatory expertise and therapeutic knowledge who guide and perform the work needed across the product development lifecycle, from initial testing to regulatory clearance, reimbursement, and commercialization. NAMSA differentiates itself with its worldwide regulatory know-how, depth of therapy-specific expertise, and a commitment to delivering proven, cost-effective solutions that speed up development. The company’s goal is to accelerate medical device product development and successful commercialization by providing comprehensive, reliable services and guidance from concept to market.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Toledo, Ohio

Founded

1967

Get referred to NAMSA

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • NAMSA completed the Labcorp medical device testing acquisition on January 8, 2026.
  • The April 30, 2026 Lexitas deal opens ophthalmic device programs across 700+ investigator sites.
  • On July 7, 2026, NAMSA agreed to sponsor United Health Products’ clinical study.

What critics are saying

  • NAMSA cut 124 St. Paul workers after the 2025 acquisition, signaling integration friction.
  • North American Science Associates v. Conforti, filed 2025 in Minnesota, shows trade-secret conflict exposure.
  • A major FDA compliance failure at one laboratory could destroy sponsor trust and halt growth.

What makes NAMSA unique

  • NAMSA bundles testing, clinical research, regulatory consulting, and reimbursement under one contract.
  • Its January 2026 Labcorp acquisition deepened U.S. biocompatibility, microbiology, analytical, and preclinical capacity.
  • The April 2026 Lexitas partnership embeds ophthalmology specialists inside NAMSA’s operating model.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

9%

1 year growth

9%

2 year growth

9%
The Bulletin
Apr 30th, 2026
NAMSA and Lexitas announce strategic partnership to deliver end-to-end ophthalmic medical device development.

NAMSA and Lexitas announce strategic partnership to deliver end-to-end ophthalmic medical device development. PR Newswire Today at 4:47am PDT Sponsors gain a single, accountable partner through all stages of product development, with Lexitas' dedicated ophthalmology expertise embedded in NAMSA's end-to-end MedTech development platform TOLEDO, Ohio and DURHAM, N.C., April 30, 2026 /PRNewswire/ - NAMSA, the global leader in MedTech contract research offering end-to-end development services, today announced a strategic partnership with Lexitas Pharma Services, the leading full-service ophthalmology contract research organization (CRO), to deliver comprehensive product development support to ophthalmic medical device sponsors. Through the partnership, Lexitas brings over 15 years of dedicated ophthalmic expertise and proven operational delivery, an extensive investigator site network, and an integrated reading center. By pairing these strengths with NAMSA's robust medical device experience and global CRO capabilities, the collaboration creates a uniquely comprehensive platform for sponsors. Together, NAMSA and Lexitas provide device innovators with a single, accountable partner for the entire development lifecycle, ensuring seamless support and coordination throughout every phase. An Embedded, Integrated Operating Model Unlike traditional referral or subcontracting arrangements, NAMSA and Lexitas will operate as a single, unified team. Lexitas clinical experts - including medical monitoring, ophthalmic imaging specialists, and site strategy leads - are integrated directly into NAMSA's project and study management structure, operating under a shared technology and process platform and a unified quality management system. Sponsors get one team, one set of accountabilities, and one line of sight across their program. What Ophthalmic Device Sponsors Gain * End-to-end product lifecycle support from preclinical and biocompatibility through IDE, pivotal trial, regulatory submission, and commercialization * Specialized ophthalmic clinical execution through Lexitas' network of 700+ investigator sites, integrated reading center, BCVA certification program, and dedicated medical monitoring team * Device-native clinical research expertise, including FDA medical device endpoint fluency, IDE strategy, and device-specific trial design * Deep therapeutic-area coverage across anterior and posterior segment ophthalmic indications, including cell and gene therapy, rare disease and advanced modalities * Global reach across the U.S., Europe, and Asia-Pacific * A single, accountable team under a single contract that reduces vendor management burden and coordination risk for sponsors Executive Perspectives Ophthalmic device sponsors have asked The Bend Bulletin for something the market hasn't been able to deliver in a coordinated way: deep device-specific expertise across the full development lifecycle, paired with specialized ophthalmic clinical execution. This partnership with Lexitas allows The Bend Bulletin to offer exactly that. NAMSA brings the end-to-end development platform ophthalmic device innovators' need; Lexitas brings the unparalleled ophthalmic expertise depth that elevates the clinical stage. Together, The Bend Bulletin is giving sponsors a rare combination: world-class device development under one contract, with the ophthalmic specialization to execute at the highest level. - Brian Smith, Chief Executive Officer, NAMSA NAMSA's global MedTech development platform is a powerful complement to what Lexitas has built in ophthalmology. By embedding its ophthalmic experts across site strategy, imaging, and medical oversight within NAMSA's operating model, the partnership enables sponsors to execute highly specialized ophthalmic trials with greater confidence and consistency. Together, NAMSA's medical device expertise and Lexitas' ophthalmology focus deliver a truly integrated approach that drives value for sponsors and meaningful impact for patients. - Jeanne Hecht, Chief Executive Officer, Lexitas Meet the Joint Team at ARVO 2026 NAMSA and Lexitas will be on-site together at the ARVO Annual Meeting, taking place May 3-6 in Denver, Colorado. Ophthalmic device sponsors and industry partners are invited to visit the Lexitas booth #10032 to connect with the joint team and learn how this strategic partnership can support and advance their development programs. About NAMSA Founded in 1967, NAMSA is a global MedTech Contract Research Organization (CRO) offering end-to-end development services across clinical research, regulatory and reimbursement consulting, biocompatibility testing, and preclinical research. With more than 1,500 experts across the U.S., Europe, and Asia-Pacific, NAMSA serves over 3,000 MedTech companies worldwide, from emerging innovators to established global manufacturers. NAMSA is dedicated to accelerating medical device product development, delivering proven solutions that move products through the development lifecycle efficiently and cost-effectively. Learn more at namsa.com. About Lexitas Pharma Services Lexitas is the leading full-service ophthalmology clinical research organization (CRO). With unmatched expertise and precision in ophthalmic research, The Bend Bulletin deliver tailored approaches, rigorous quality standards, and unwavering commitment to operational success. Its team of experts, including ophthalmologists, optometrists, and clinical operations specialists, brings extensive medical, scientific, regulatory, and operational knowledge across all ophthalmology subspecialties. With a deep understanding of patient treatment pathways, provider and research networks, and market opportunities, Lexitas provides customized solutions that support your needs at every stage of development. Visit lexitas.com for more information. SOURCE NAMSA This is a paid placement. For further inquiries, please contact PR Newswire directly.

PR Newswire
Mar 3rd, 2025
Namsa Completes Acquisition Of Wuxi Apptec Us Medical Device Testing Business

TOLEDO, Ohio, March 3, 2025 /PRNewswire/ -- NAMSA, a leading US based MedTech testing, clinical and regulatory consulting firm, announced that it finalized its acquisition of WuXi AppTec's US medical device testing operations on February 28.The acquisition brings together two of the most trusted names in medical device biological safety testing, serving more than 4,000 manufacturers worldwide.Lisa Olson, NAMSA Senior Vice President of Global Laboratory Services notes: "Together, we now have unmatched scientific expertise in biocompatibility, microbiology, preclinical and extractables and leachables testing. With the addition of WuXi AppTec medical device testing facilities in the US, we now have more scientists, more lab capacity and more expertise with a wider variety of medical devices than any other company. This combined expertise will continue to enable our work with clients to develop testing and consulting strategies tailored to their specific device and regulatory pathways."NAMSA has been expanding its reach in recent years as it continues to diversify its offering beyond biological safety testing. Since 2021, the company has acquired no fewer than six companies focused on preclinical or clinical research, making NAMSA one of the leading MedTech focused CROs. Brian Smith, NAMSA's recently appointed CEO noted: "This acquisition is part of our larger strategy to broaden our service offering and solidify our position as the go-to resource for manufacturers bringing new life-saving technologies to market while upholding the same high standards of client focused service you have come to expect from NAMSA."About NAMSAHelping medical device Sponsors improve healthcare since 1967, NAMSA is a leading global MedTech testing, clinical and regulatory consulting firm. With a deep pool of testing, clinical and regulatory experts, and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development

PR Newswire
Feb 24th, 2025
Brian P. Smith Joins Namsa As Chief Executive Officer; Brings 15+ Years Of Life Sciences Leadership Expertise To Role

TOLEDO, Ohio, Feb. 24, 2025 /PRNewswire/ -- NAMSA, a world-leading MedTech testing, clinical and regulatory consulting firm, announced today that Brian P. Smith has taken on the role of NAMSA's next Chief Executive Officer. Most recently, Brian served as the Chairman and Chief Executive Officer of Ad-Tech Medical Instrument Corp., a leading US neuro-diagnostic company.Andre-Michel Ballester, NAMSA's outgoing CEO, will transition back into his role as a managing partner of ARCHIMED, the healthcare-focused global private equity firm that holds a majority stake in NAMSA.Ballester led the search for a new CEO and notes: "Brian is globally recognized as a respected healthcare executive, having served in various leadership roles over the past 15 years as a Board Member, Operating Partner, Chairman of the Board, and Chief Executive Officer with extensive experience in operational, commercial, and innovation strategies. Brian's international experience, having lived and worked in Hong Kong, Shanghai, and Singapore, will be invaluable as we continue to expand our global footprint."Smith adds: "I am thrilled to join an organization with the history, reputation, and contribution to improved patient outcomes that NAMSA has repeatedly demonstrated for decades. I look forward to making my own contribution to this ongoing success story."NAMSA recently announced that it had signed a definitive agreement to purchase the US medical device testing operations of WuXi AppTec

BioSpace
Jan 17th, 2025
NAMSA Acquires the U.S. Medical Device Testing Operations of WuXi AppTec, Solidifying its Position as the Leader in MedTech Testing and Clinical Research

Under the agreement, NAMSA will acquire WuXi AppTec facilities in Minnesota and Georgia.

BioSpectrum Asia
Oct 16th, 2024
Japanese med tech leader Terumo announces strategic outsourcing partnership with Namsa

Japanese med tech leader Terumo announces strategic outsourcing partnership with Namsa.